A screening study of the clinically approved HDAC inhibitors showed that romidepsin, panobinostat, givinostat hydrochloride monohydrate, CAY10603, and sirtinol were able to inhibit the cellular entry of COVID-19 [68]. Here, HDAC9 is linked to COVID-19.